Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
| General Information | |
| Organism | Homo sapiens, human |
| Cell Line Description | KU-19-19 is a human bladder cancer cell line derived from a high-grade transitional cell carcinoma (urothelial carcinoma) of the bladder. The cell line exhibits an epithelial-like morphology and grows as an adherent monolayer under standard culture conditions. Classified as a poorly differentiated cell line, KU-19-19 retains key pathological features of advanced human urothelial carcinoma, including characteristic genetic alterations and aberrant signaling pathways commonly found in invasive bladder cancer. Cytogenetically, KU-19-19 displays an aneuploid karyotype characterized by various numerical and structural chromosomal rearrangements. Due to its representative bladder cancer phenotype, KU-19-19 has become a vital in vitro model for investigating the molecular mechanisms underlying the pathogenesis, progression, and invasive potential of bladder urothelial carcinoma. Furthermore, it serves as a valuable biological platform for screening novel chemotherapeutic agents, testing targeted therapies, and conducting functional genomic studies. |
| Tissue | Bladder |
| Disease | Transitional Cell Carcinoma; Bladder Cancer (Urothelial Carcinoma) |
| Morphology | Epithelial |
| Age | 76 years |
| Gender | Male |
| Product Format | Frozen |
| Growth Mode | Adherent |
| Biosafety Level | 1 (Biosafety classification is based on U.S. Public Health Service Guidelines) |
| Applications | 1. Research on the biology of human urothelial carcinoma and bladder cancer progression; 2. In vitro screening and preclinical evaluation of targeted anticancer therapies and chemotherapeutic agents; 3. Research on the mechanisms of bladder cancer cell proliferation, invasion, and drug resistance; 4. Functional genomic analysis, target validation, and CRISPR/Cas9 knockout screening. |
| Shipped In | Dry ice |
| Storage Temperature | −196°C |
| Characteristics | |
| Karyotype | Aneuploid |
| Tumorigenic | Yes, tumorigenic in immunocompromised mice |
| Genetic Profile | TP53 mutation; HRAS / KRAS pathway alterations |
| Mycoplasma Test | Negative |
| Culture Conditions and Handling | |
| Subculturing | 1. Remove and discard the culture medium. 2. Briefly rinse the cell monolayer with PBS (without Ca2+/Mg2+) to completely remove residual serum. 3. Add 1.0 to 2.0 mL of 0.25% trypsin-0.03% EDTA solution and incubate at 37°C until the cell monolayer detaches (typically 2 to 5 minutes). 4. Add fresh complete growth medium to neutralize the trypsin and gently pipette up and down to prepare a single-cell suspension. 5. Subculture the cell suspension into new culture vessels. |
| Medium Renewal | Every 2 to 3 days |
| Subcultivation Ratio | A split ratio of 1:3 to 1:6 is recommended |
| Culture Conditions | Atmosphere: Air, 95%; CO2, 5%; Temperature: 37°C |
| Cryopreservation | Complete growth medium supplemented with 5% to 10% (v/v) DMSO |
| Cat.No. | Product Name | Price |
|---|---|---|
| CSC-RR0341 | GFP Reporter Cell Line - KU-19-19 | Inquiry |
| CSC-RO01499 | OVAL Stable Cell Line - KU-19-19 | Inquiry |
| CSC-RO01752 | GFP/OVAL Stable Cell Line - KU-19-19 | Inquiry |
| CSC-RO02005 | Luc/OVAL Stable Cell Line - KU-19-19 | Inquiry |
| CSC-RO02258 | GFP/Luc/OVAL Stable Cell Line - KU-19-19 | Inquiry |
The above is only part of a part of cell line products. If you don't find the cell line you want, Creative Biogene can also provide stable cell line generation service with the best prices and fastest turnaround time for you! Contact us for more information or to request a quote.
Copyright © 2026 Creative Biogene. All rights reserved.